Long-term observation of fibrillation cycle length in patients under angiotensin II receptor blocker therapy for chronic atrial fibrillation-Reference-Cited by-同舟云学术

Long-term observation of fibrillation cycle length in patients under angiotensin II receptor blocker therapy for chronic atrial fibrillation

Published:2012-02 Issue:1 Volume:28 Page:34-40
ISSN:1880-4276
Container-title:Journal of Arrhythmia
language:en
Short-container-title:Journal of Arrhythmia

Author:

Kishihara Jun,Niwano Shinichi,Niwano Hiroe,Aoyama Yuya,Ishikawa Shoko,Oikawa Jun,Sato Akira,Murakami Masami,Kiryu Michiro,Izumi Tohru

Funder

Ministry of Education, Culture, Sports, Science, and Technology of Japan

Ministry of Health and Welfare of Japan

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Reference31 articles.

1. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation;Kumagai;J Am Coll Cardiol,2003

2. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation;Kumagai;Circulation,2000

3. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial;Julius;Lancet,2004

4. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program;Ducharme;Am Heart J,2006

5. ValãHeFT investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure–results from the Valsartan Heart Failure Trial (Val-HeFT);Maggioni;Am Heart J,2005

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. News on angiotensin II and atrial fibrillation : from the molecular to the pathophysiological.;Revista Ciencias Biomédicas;2021-04-15